fig2

Figure 2. 5-hydroxymethylcytosine modification profiling and genome-wide distribution in PLGC and healthy individuals. (A) Distribution of 5hmC in PLGC and healthy individuals at different pathological stages; (B) Principal component analysis results of the two groups; (C) Mean log2 fold change in different genomic regions, including Distal Intergenic, Promoter, Exon, Intron, and 3’UTR; (D) Overall distribution of 5hmC sites in different genomic regions; (E) 5hmC motif analysis results in healthy samples; (F) 5hmC motif analysis results in PLGC samples. PLGC: Precancerous lesion of gastric cancer; 5hmC: 5-hydroxymethylcytosine; TSS: transcription start site; TTS: transcription termination site; PCA: principal component analysis; PC: principal component; UTR: untranslated region; ERG: ETS-related gene; GATA3: GATA binding protein 3; TRPS1: trichorhinophalangeal syndrome type I; ETV2: ETS variant transcription factor 2; EWS: ewing sarcoma gene.